Shares of Omnicell (NASDAQ: OMCL) , a medication management company focused on automating the pharmacy , rose 13% as of 11:20 a.m. EDT on Friday. The jump was caused by a well-received second-quarter earnings report that featured expectation-topping guidance.
Here's a review of the highlights from the report:
- Non-GAAP revenue jumped 4% to $188 .7 million.
- Non-GAAP gross margin expanded 380 basis points to 49.1%.
- Non-GAAP net income grew 44% to $18 .4 million.
- Non-GAAP EPS was $0.46 per share. This was far ahead of the $0.39 that Wall Street had projected.
Image source: Getty Images.
Turning to guidance, here's what the company is projecting:
- Third-quarter revenue will land between $200 million and $206 million. The midpoint of this range is ahead of what market watchers were expecting.
- Third-quarter EPS is expected to land between $0.52 and $0.57.
- Full-year 2018 revenue is projected to land between $780 million and $800 million. The middle of this range is in line with Wall Street's estimate.
- Full-year 2018 EPS is expected to land between $1.90 and $2.05. The midpoint of this range is ahead of the $1.95 that market watchers were expecting.
Given the upbeat results, it isn't hard to figure out why shares are up by double digits today.
Omnicell's second-quarter results show that the business is scaling nicely as revenue continues to tick higher. That's a great development for investors and bodes well for profit growth from here as the company continues to ride the pharmacy automation wave.
10 stocks we like better than Omnicell
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Omnicell wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.